Seng H. Cheng

Genzyme Corporation, USA 0000-0002-0359-6300

Seng H. Cheng holds a Ph.D. degree. He is a Group Vice President of Genetic Diseases Science at Genzyme, a Sanofi Company. Dr. Cheng received his B.S. (1979) and Ph.D. (1983) degrees in biochemistry from the University of London, UK. He is trained as a postdoctoral fellow at the National Institute for Medical Research in London, U.K. and at Integrated Genetics Inc., where he performed research on the molecular basis of tumorigenesis. He was a Staff Scientist at Integrated Genetics in 1987 and joined Genzyme Corporation in 1989 to work on several discovery projects including the structure and function of the cystic fibrosis transmembrane conductance regulator. Since 1993, he has managed the efforts at Genzyme Corporation to develop synthetic and viral gene delivery vectors for several disease indications. These efforts led to one of the first clinical testing of gene therapy for cystic fibrosis for which he was awarded the Genzyme President’s award in 1996. He has published over 200 scientific research articles and is a coauthor on 31 issued patents in the area of biotechnology. He is a member of the editorial boards of Molecular Therapy, Journal of Gene Medicine, Current Gene Therapy, Current Pharmaceutical Biotechnology and The Open Genomics, and Gene Therapy Journals. Presently, he is responsible for the discovery and translational research activities in genetic and neurogenetic diseases at Genzyme.

Biography Updated on 31 July 2011

Scholarly Contributions [Data Provided by scopus]

download